	yst WebQ	Home	Help Lo	gout	Your Accou	unt (pharm54	43)	Go
Build C	Quiz		🛃 Build	Pr	<u>eview</u>	Summa Summa	ary 🧲	R
🗹 quiz 4	ı							
	This quiz has 88 subm cause multiple version see a version of the qu how results are affected	is of a question, "N/A	on to be show	n in th	e results.	If the part	icipant c	lid
	ons or general content to you f question types.	ur survey by sele	ecting an item fro	om the dr	op-down me	enu and clicki	ng "Add".	Vie
Add item	Short response		at	end o	f survey	Add		
Question What ma	akes a drug a "drug" in		lium.					
	is recommised in on off	icial compend	lium.					
	is recognized in an off t is intended for use in	treatment of						
II. that i III. that Answers O a. I	t is intended for use in it is intended to affect		disease.	e body.				
II. that i III. that Answers O a. I O b. I O c. I	t is intended for use in it is intended to affect only II only , and II		disease.	e body.				
II. that i III. that Answers O a. I O b. I O c. I O d. I	t is intended for use in it is intended to affect only II only , and II and III		disease.	e body.				
II. that i III. that Answers O a. I O b. I O c. I O d. I	t is intended for use in it is intended to affect only II only , and II and III , II and III		disease.	e body.		Ро	int value	5:
II. that i III. that Answers 0 a. I 0 b. I 0 c. I 0 d. I ✓ 0 e. I	t is intended for use in it is intended to affect only II only , and II and III , II and III	structure or t	disease.			Ро	int value	2: _

Question

A cosmetic is not a drug because

Answers

O it is intended for a trivial disease.

 \checkmark O it is intended for cleaning, beautifying, and promoting attractiveness.

Feedback

(i) The term "cosmetic" means (1) articles intended to be rubbed, poured, sprinkled, or sprayed introduced into or otherwise annlied to the human hody or any nart thereof for cleansing

https://catalysttools.washington.edu/tools/secure/webq3/

beautifying, promoting attractiveness, or altering the appearance, and (2) articles intended for u
as a component of any such articles; except that such term shall not include soap.

Required: 🔽

Point value: 1

Insert page break

Position 3: Multiple choice - one answer (button) <u>Hide question details</u>	<u>Edit</u>	Preview	<u>Copy</u>	De
Question The FDA has penalties for:				
I. adulteration.				
II. misbranding.				
III. overcharging of patients.				
Answers				
O a. I only				
O b. II only				
✓ O c. I and II only				
Od. Land III only				
◯e. I, II and III				
Note: Sonsors are sometimes allowed to charge for investigational investigational medical devices (more common), but only to the ex	•			
cost of research and production: 21CFR312.7(d)(3) Noncommercial Under this section, the sponsor may not commercialize an investigation larger than that necessary to recover costs of manufacture, researce the investigational drug.	lization ational	of investion drug by ch	gational arging a	dru(a pri
Under this section, the sponsor may not commercialize an investigation larger than that necessary to recover costs of manufacture, research	lization ational	of investig drug by ch elopment,	gational arging a	druç a pri idlin
Under this section, the sponsor may not commercialize an investigation larger than that necessary to recover costs of manufacture, researe the investigational drug.	lization ational	of investig drug by ch elopment,	ational arging a and har	druç a pri idlin
Under this section, the sponsor may not commercialize an investigating larger than that necessary to recover costs of manufacture, researce the investigational drug. Required:	lization ational	of investig drug by ch elopment,	ational arging a and har	druç a pri idlin
Under this section, the sponsor may not commercialize an investigation of the investigational drug. Required: Position 4: Multiple choice - one answer (button)	lization ational ch, dev	of investig drug by ch elopment, Po	arging a and har int value	dru(a prie idlin e: 1
Under this section, the sponsor may not commercialize an investigational larger than that necessary to recover costs of manufacture, research the investigational drug. Required: Required: Insert page break Position 4: Multiple choice - one answer (button) Hide question details Question	lization ational ch, dev	of investig drug by ch elopment, Po	arging a and har int value	dru(a prie idlin e: 1
Under this section, the sponsor may not commercialize an investigat larger than that necessary to recover costs of manufacture, research the investigational drug. Required: Required: Position 4: Multiple choice - one answer (button) Hide question details Question Pharmaceutical compounding:	lization ational ch, dev	of investig drug by ch elopment, Po	arging a and har int value	dru(a prie idlin e: 1
Under this section, the sponsor may not commercialize an investigat larger than that necessary to recover costs of manufacture, research the investigational drug. Required: Position 4: Multiple choice - one answer (button) <u>Hide question details</u> Question Pharmaceutical compounding: I. is outlined in FDA's "9 points of light".	lization ational ch, dev	of investig drug by ch elopment, Po	arging a and har int value	dru(a prie idlin e: 1
Under this section, the sponsor may not commercialize an investigational drug larger than that necessary to recover costs of manufacture, researce the investigational drug. Required: Required: Insert page break Position 4: Multiple choice - one answer (button) Hide question details Question Pharmaceutical compounding: I. is outlined in FDA's "9 points of light". II. questions are jurisdiction of State Boards of Pharmacy.	lization ational ch, dev	of investig drug by ch elopment, Po	arging a and har int value	dru(a prie idlin e: 1
Under this section, the sponsor may not commercialize an investigational drug investigational drug. Required: Position 4: Multiple choice - one answer (button) Hide question details Question Pharmaceutical compounding: I. is outlined in FDA's "9 points of light". II. questions are jurisdiction of State Boards of Pharmacy. III. Presumes a prescriber-patient-pharmacist relationship.	lization ational ch, dev	of investig drug by ch elopment, Po	arging a and har int value	dru(a prie idlin e: 1
Under this section, the sponsor may not commercialize an investigational drug investigational drug. Required: Position 4: Multiple choice - one answer (button) Hide question details Question Pharmaceutical compounding: I. is outlined in FDA's "9 points of light". II. questions are jurisdiction of State Boards of Pharmacy. III. Presumes a prescriber-patient-pharmacist relationship. Answers	lization ational ch, dev	of investig drug by ch elopment, Po	arging a and har int value	dru(a prie idlin e: 1
Under this section, the sponsor may not commercialize an investigational drug. Required: Position 4: Multiple choice - one answer (button) Hide question details Ouestion Pharmaceutical compounding: is outlined in FDA's "9 points of light". questions are jurisdiction of State Boards of Pharmacy. III. Presumes a prescriber-patient-pharmacist relationship. Answers a. I only	lization ational ch, dev	of investig drug by ch elopment, Po	arging a and har int value	dru(a prie idlin e: 1
Under this section, the sponsor may not commercialize an investigational drug. Required: Position 4: Multiple choice - one answer (button) Hide question details Question Pharmaceutical compounding: I. is outlined in FDA's "9 points of light". II. questions are jurisdiction of State Boards of Pharmacy. III. Presumes a prescriber-patient-pharmacist relationship. Answers O a. I only O b. III only O b. III only O b. III only O b. III only O b. III only O b. III only O b. III	lization ational ch, dev	of investig drug by ch elopment, Po	arging a and har int value	dru(a prie idlin e: 1

https://catalysttools.washington.edu/tools/secure/webq3/

Required: 🔽		Ро	int value	e: 1
Insert page break				
Position 5: Multiple choice - one answer (button) <u>Hide question details</u>	<u>Edit</u>	Preview	<u>Copy</u>	De
Question Many pharmacies lose their licenses secondary to fraudulent billing	proced	lures.		
Answers				
✓Oa. True.				
O b. False.				
Required: 🔽		Ро	int value	e: 1
Insert page break				
Position 6: Multiple choice - one answer (button) <u>Hide question details</u>	<u>Edit</u>	<u>Preview</u>	<u>Copy</u>	<u>De</u>
Question Fraudulent billing procedures have root causes that include:				
I. Complacency.				
II. Limited goverance and oversight.				
III. Lack of rigorous risk assessment.				
Answers O a. I only				
O b. III only				
Oc. I and II only				
\bigcirc d. I and III only				
✓Oe. I, II and III				
Required:		Po	int value	e: 1
•		10		
Insert page break				
Position 7: Multiple choice - one answer (button) <u>Hide question details</u>	<u>Edit</u>	Preview	<u>Copy</u>	<u>De</u>
Question Purposeful Fraud includes:				
I. dispensing generic Rx for brand Rx.				
II. dispense one strength and bill for another.				
III. "Ghost" patients.				
Answers				
O a. I only				
O b. III only				
Oc. I and III only				

Od.	I	and	П	only
-----	---	-----	---	------

✓Oe. I, II and III

Required: 🔽

Point value: 1

Question

From FDA's perspective, a drug is differentiated from a medical device because

I. manufacturer's intent that the article modify form and function of the body

II. manufacturer's intent that the article be used in the diagnosis, cure, mitigation, treatment or prevention of disease

 $\ensuremath{\mathsf{III}}$. article's attributes do not achieve their primary intended purpose through chemical action within or on the body

Answers

Oa. I only

✓Ob. III only

Oc. I and II only

Od. I and III only

O e. I, II and III

Feedback

21USC321 (h) The term "device" (except when used in paragraph (n) of this section and in secti 301(i), 403(f), 502(c), and 602(c)) means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any componer part, or accessory, which is— (1) recognized in the official National Formulary, or the United Sta Pharmacopeia, or any supplement to them, (2) intended for use in the diagnosis of disease or ot conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other anima or (3) intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes.

Required: 🗹

Point value: 1

Insert page break

Position 9: Multiple choice - one answer (button)
 <u>Hide question details</u>
 <u>Edit</u> <u>Preview</u> <u>Copy</u> <u>De</u>

Question

Whether a practice is considered treatment or research:

- I. depends on intent of provider.
- II. depends on novel nature of practice.
- III. depends upon whether it is supervised by IRB.

Answers

https://catalysttools.washington.edu/tools/secure/webq3/

✓Oa. I only				
O b. III only				
O c. I and II only				
O d. I and III only				
O e. I, II and III				
Required: 🔽		Ро	int value	ə: 1
Insert page break				
Position 10: Multiple choice - one answer (button) <u>Hide question details</u>	<u>Edit</u>	Preview	<u>Copy</u>	De
Question The Belmont Report differs from the "Georgetown mantra" in that Answers O a. Autonomy O b. Beneficence O c. Justice ✓ O d. Nonmaleficence	it fails t	o mention		
Required:		Ро	int value	ə: 1
Save for later		Tota	l points:	10

Questions, comments, or problems? <u>Contact us</u> or email *catalysthelp@u.washington.edu* Copyright © 1998-2005 Educational Partnerships and Learning Technologies <u>The University of Washington</u>